Shares of Inovio Pharmaceuticals INO increased 2.94% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share fell 4.00% year over year to ($0.26), which missed the estimate of ($0.19).
Revenue of $236,178,000 up by 27145.14% year over year, which beat the estimate of $3,050,000.
Outlook
Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.
Inovio Pharmaceuticals hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2021/38428
Price Action
52-week high: $33.79
Company's 52-week low was at $2.19
Price action over last quarter: down 40.29%
Company Overview
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
